OP0077 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Psoriatic Arthritis with and without Prior Anti-Tumor Necrosis Factor Exposure: 96-Week Outcomes from the Rapid-Psa Trial

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 90.1-90
Author(s):  
P.J. Mease ◽  
R. Fleischmann ◽  
J. Wollenhaupt ◽  
A. Deodhar ◽  
D. Gladman ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Certolizumab Pegol ◽  
Safety And Efficacy ◽  
Necrosis Factor

New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol

2015 ◽  
Vol 93 (0) ◽  
pp. 70-72 ◽  
Author(s):  
A. Cauli ◽  
M. Piga ◽  
E. Lubrano ◽  
A. Marchesoni ◽  
A. Floris ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Certolizumab Pegol ◽  
New Approaches ◽  
Necrosis Factor

scholarly journals Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure

Circulation ◽  
1999 ◽  
Vol 99 (25) ◽  
pp. 3224-3226 ◽  
Author(s):  
Anita Deswal ◽  
Biykem Bozkurt ◽  
Yukihiro Seta ◽  
Semahat Parilti-Eiswirth ◽  
F. Ann Hayes ◽  
...  
Keyword(s):  
Heart Failure ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Advanced Heart Failure ◽  
Safety And Efficacy ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document